Skip to main content

Table 2 Visits, hospitalizations, relapses and inactivity days over the 12 weeks

From: Fluticasone furoate/Vilanterol 92/22 μg once-a-day vs Beclomethasone dipropionate/ Formoterol 100/6 μg b.i.d.: a 12-week cost analysis in mild-to-moderate asthma

 

Overall cohort

PS-matched cohort

 

Group A

Group B

Difference Group B – Group A

p

Group A

Group B

Difference Group B – Group A

p

n. GP Visits mean (±SE)

0.84 (±0.09)

0.38 (±0.12)

-0.46

<0.001

0.85 (±0.15)

0.38 (±0.12)

-0.47

<0.001

Specialist visits mean (±SE)

0.66 (±0.08)

0.28 (±0.07)

-0.38

<0.001

0.68 (±0.11)

0.28 (±0.07)

-0.40

<0.001

n. Hospitalizations mean (±SE)

0.13 ± 0.04

0.08 ± 0.04

-0.05

0.372

0.15 ± 0.06

0.08 ± 0.04

-0.08

0.11

Days of Hospitalizations mean (±SE)

0.19 ± 0.07

0.08 ± 0.04

-0.12

0.348

0.28 ± 0.12

0.08 ± 0.04

-0.20

0.09

n. Relapses mean (±SE)

0.53 (±0.08)

0.28 (±0.07)

-0.26

0.106

0.53 (±0.12)

0.28 (±0.07)

-0.25

0.12

Days of inactivity mean (±SE)

1.62 (±0.26)

0.68 (±0.20)

-0.95

0.088

1.53 (±0.37)

0.68 (±0.20)

-0.85

0.12

  1. Group A: patients treated with Beclomethasone dipropionate/Formoterol 100/6 μg b.i.d
  2. Group B: patients treated with Fluticasone furoate/Vilanterol 92/22 μg once-a-day
  3. GP general practitioner, [95 % CI confidence interval], p refers to Wilcoxon rank-sum test